A Form 4 filed on August 7, 2026, disclosed that Brian Corvese, a director of Agenus Inc. (NASDAQ:AGEN), was awarded a stock option covering 100,000 shares of common stock on August 5, 2026.

Key Highlights

  • Grant date: August 5, 2026, with an expiration date of August 5, 2036.
  • Option size: 100,000 shares of Agenus Inc. common stock awarded to director Brian Corvese.
  • Exercise price: $7.78 per share, acquired at a derivative price of $0.00.
  • Vesting schedule: One-third vests on the first anniversary of the grant date, with the remaining two-thirds vesting in two equal annual installments thereafter.
  • Plan: Awarded under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan.
  • Resulting ownership: 100,000 derivative securities beneficially owned directly following the transaction.

Agenus Director Receives 100,000-Share Option Under 2019 Equity Plan

According to the Form 4 filing submitted to the U.S. Securities and Exchange Commission, Brian Corvese, identified as a director of Agenus Inc., received a stock option grant on August 5, 2026. The option covers 100,000 shares of Agenus common stock at an exercise price of $7.78 per share and carries an expiration date of August 5, 2036. The filing lists the price of the derivative security as $0.00, indicating no cost to the reporting person at grant.

The filing states the option was "awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan." Per the explanation of responses, the award vests over three years: one-third on the first anniversary of the grant date and the remaining two-thirds in two equal annual installments after that. Following this transaction, the filing reports Corvese directly holds 100,000 derivative securities beneficially.

The Form 4 was signed by Melissa Orilall as attorney-in-fact for Brian Corvese and dated August 7, 2026. No non-derivative securities transactions were reported in Table I of the filing. The transaction code listed is "A," indicating an acquisition.

What Was Disclosed

Agenus Inc. director Brian Corvese received a stock option for 100,000 shares at an exercise price of $7.78, granted August 5, 2026, under the company's 2019 Amended and Restated Equity Incentive Plan, with a three-year vesting schedule and a ten-year term.